Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile

BMC Infectious Diseases

Table 3 Frequency and type of symptoms and presence of SARS-CoV-2 antibodies. Chile 2020

Symptoms	Participants			Symptoms in seropositive^a (%)*	Symptoms in seronegative^a (%)*	OR (95% CI)^b
Symptoms	Total (n = 2493)	Seropositive (n)	Seronegative (n)	Symptoms in seropositive^a (%)*	Symptoms in seronegative^a (%)*	OR (95% CI)^b
Fever	173	65	108	24.9	4.8	6.6 (3.4–12.8)
Cough	237	63	174	27	8.2	4.1 (2.0–8.8)
Odynophagia	326	75	251	29.5	12.1	3.0 (1.7–5.4)
Dyspnea	147	49	98	15	4.6	3.7 (1.8–7.4)
Headache	434	113	321	45.9	15.9	4.5 (2.5–8.2)
Myalgia	306	94	212	39.4	10.7	5.4 (3.1–9.5)
Chest pain	108	45	63	22.2	3.2	8.8 (3.4–22.9)
Abdominal pain/diarrhea	168	50	118	19.2	7.5	3.0 (1.3–6.5)
Fatigue/prostration	181	61	120	24.9	5.5	5.7 (3.0–10.9)
Anosmia	100	74	26	23.3	1.0	30.0 (12.1–74.6)
Dysgeusia	89	66	23	21.6	0.8	32.9 (11.6–93.9)

OR, odds ratio; 95% CI, 95% confidence interval. ^aWeighted for sampling weights. ^bReference category = seronegative

ISSN: 1471-2334